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Abstract
Background: Hsp90 proteins are important therapeutic targets for many anti-cancer drugs in clinical trials. Geldanamycin
(GA) was identified as the first natural inhibitor of Hsp90, increasing evidence suggests that GA was not a good choice for
clinical trials. In this study, we investigated two new non-benzoquinone geldanamycin analogs of Hsp90 inhibitors, DHQ3
and 17-demethoxy-reblastatin (17-DR), to explore the molecular mechanisms of their anti-cancer activity in vivo and vitro.
Methods: MTT and colony formation assays were used to measure cell viability. Flow cytometry, DAPI staining, ATP assay,
electron microscopy, western blots, siRNAs transfection and immunofluorescence were used to determine the molecular
mechanism of DHQ3- or 17-DR-induced different forms of death in human breast cancer MDA-MB-231 cells. Malachite
green reagent was used to measure ATPase activity of the analogs.
Results: DHQ3 and 17-DR presented efficiently inhibitory effect in MDA-MB-231 cell lines, and DHQ3 induced necroptosis
by activation of the RIP1-RIP3-MLKL necroptosis cascade. And DHQ3-induced cell death was inhibited by a necroptosis
inhibitor, necrostatin-1 (Nec-1), but not by a caspase inhibitor z-VAD-fmk. On the other hand, 17-DR induced apoptosis in
MDA-MB-231 cells, indicating a caspase-dependent killing mechanism. We further demonstrated that down-regulation of
RIP1 and RIP3 by siRNA protected against DHQ3 but not 17-DR induced cell death. These results were confirmed by
electron microscopy. DHQ3 and 17-DR induced the degradation of Hsp90 client proteins, and they showed strong
antitumor effects in MDA-MB-231 cell-xenografted nude mice.
Conclusions: These findings supported that DHQ3 and 17-DR induce different forms of death in some cancer cell line via
activation of different pathways. All of the results provided evidence for its anti-tumorigentic action with low
hepatotoxicity in vivo, making them promising anti-breast cancer agents.
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Background
Breast cancer is the most common life-threatening carcin-
oma, affecting women worldwide. Although considerable
progress in treatment development has been made over the
past decades, the incidence of breast cancer has been rising
sharply in developing countries [1]. Therefore, there is a re-
quirement to develop novel therapeutic agents to treat
breast cancer.
Hsp90 and its co-chaperones stabilize various
growth factor receptors, signal transduction proteins
such as PI3K and AKT, and mutant proteins in can-
cerous cells [2, 3]. Inhibiting Hsp90 in these cells se-
lectively induces the degradation of over-expressed or
mutated proteins, thereby curbing cancer cell growth.
Increased expression levels of Hsps are common in
human breast cancers, making them potential select-
ive targets [4]. Small molecular Hsp90 inhibitors
have been developed and demonstrated promising
anti-cancer profiles [5]. Geldanamycin (GA) was
identified as the first natural inhibitor of Hsp90.
However due to its poor aqueous solubility and its
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toxicity, GA has not been considered in clinical trials
[6, 7]. Therefore, new GA derivatives with improved
pharmacological profiles are needed. DHQ3 and 17-
demethoxy-reblastatin (17-DR), two non-quinone GA
analogs, were obtained from a genetically modified
strain of Streptomyces hygroscopicus JCM442 and
their structures have been determined [8, 9]. The
phenolic structure effectively improved the water
solubility as compared to the benzoquinone struc-
ture. Their ATPase inhibition activity has been
proved, but their anti-tumor proliferative activities
remain unclear.
Our previous work showed that the GA analogs could
induce cell death in breast cancer cells [10] and human
hepatocellular carcinoma cells [11]. Historically, cell
death has been classified into distinct forms, including
apoptosis, necrosis and autophagy. Caspase activation
plays an essential role in the apoptotic process [12, 13].
In the absence of caspase activation, a regulated cellular
necrosis, called necroptosis, prevails [14–16]. In the
necroptosis process, receptor-interacting protein (RIP)
kinase family works together with death receptor pro-
teins to regulate cell death. Recent studies have revealed
that RIP3 kinase functions with RIP1 at the intersec-
tions of apoptosis, necroptosis, and cell survival [17].
RIP3 is a key determinant of necroptosis [18], the serine
phosphorylation is required for the interaction of RIP3
with its substrate mixed lineage kinase domain-like pro-
tein (MLKL) [19]. RIP1 and RIP3 form the ‘necrosome’
and subsequently phosphorylate MLKL, causing
necroptosis in various cell types [20–22]. Emerging evi-
dence suggests that CaMKII [23], Hsp90 and co-
chaperone CDC37 [5] are required for RIP3 activation
during necroptosis. In addition, necroptosis can be spe-
cifically inhibited by necrostain-1 (Nec-1), a small mol-
ecule targeting the death domain kinase RIP1 [14].
Herein, we demonstrated that DHQ3 induces
necroptosis in MDA-MB-231 cells through effects on
the RIP1-RIP3-MLKL cascade, while 17-DR induces
caspase-dependent apoptosis. However, these results
were not observed in other cancer cell lines. These
two new compounds showed highly effective
antitumor activity in vitro and in vivo against breast




DHQ3 and 17-DR were obtained as described previously.
They were dissolved in dimethyl sulfoxide (DMSO,
Biosharp, Hefei, China) and stored at −20 °C. MG132,
Nec-1, DAPI (4,6-diamidino-2-phenylindole), and 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). PI assay kits were purchased from Beyotime
Institute of Biotechnology (Wuhan, China) and the
Annexin V FITC/PI apoptosis detection kit was purchased
from Nanjin KeyGen Biotech (Nanjing, China). The ATP
Assay kit was purchased from Merck KGaA (Darmstadt,
Germany). Lipofectamine 2000 was purchased from Invi-
trogen (USA). The following antibodies were used: anti-
Mcl-1, anti-PARP, anti-RIP1, anti-RIP3 (Santa Cruz Bio-
technology, Santa Cruz, CA, USA); anti-Bcl-2, anti-Bax,
anti-HIF1a, anti-CDK4, anti-Her2, anti-EGFR (Protein-
tech, Chicago, IL, USA); anti-Hsp70, anti-Hsp90, anti-Akt
(Cell Signaling Technology, Beverly, Massachusetts, USA);
anti-caspase 3 and anti-caspase 8 (ENZO, Switzerland);
anti-C-Raf (Abcam, Cambridge, MA, USA); and anti-β-
actin (BioSharp, Hefei, China).
Cell lines and cell culture
The human breast cancer cell lines MDA-MB-231,
MCF-7 and T-47D, human hepatocellular carcinoma
(HCC) cell lines HepG2 and SMMC7721, human naso-
pharyngeal carcinoma cell lines HNE1 and CNE-2Z, hu-
man gastric cancer cell line SGC7901, human
endometrial cancer cell line ISK, and human non-small
cell lung cancer cell line A549 were bought from Shang-
hai Cell Bank (Shanghai, China). The human colon car-
cinoma SW480 was obtained from the American Type
Culture Collection (Manassas, VA, USA). Cells were ob-
tained, frozen and cultured in our laboratory. The cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco) or Roswell Park Memorial Institute
(RPMI)-1640 medium (Gibco), supplemented with 10 %
fetal bovine serum (FBS), 100 U/mL penicillin, and
100 μg/mL streptomycin. Cells were grown in an atmos-
phere containing 5%CO2 at 37 °C.
Cell viability assay
Cell were plated at a density of 6 × 103 cells/well in a 96-
well plate for 24 h, and then treated with different con-
centrations of analogs. At time points, 15 μL MTT
(5 mg/mL in phosphate-buffered saline, PBS) was added
to the wells and the plates were incubated further for
4 h at 37 °C. Then, the solution was removed and
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replaced with 150 μL of DMSO and the absorbance was
measured at 490 nm using a plate reader.
Colony formation assay
Cells were cultured in 6-well plates (6000 cells/well)
overnight. The medium was then exchanged with fresh
medium containing DHQ3 or 17-DR. The plates were
incubated under cell culture conditions for another
5 days, at which point the medium was removed and the
cells were washed twice with PBS and fixed with parafor-
maldehyde for 10 min at – 20 °C. The colonies were
stained with 2 % crystal violet for 10 min, washed with
double-distilled water and dried at room temperature,
before being counted.
Flow cytometry
Cells (1.2 × 105cells/well) were seeded in 12-well plates
and treated with the analogs. After treatment for 24 h,
cells were collected and mixed with 50 μg/mL propi-
dium iodide (PI). Cells permeable to PI were counted by
Accuri C6 flow cytometry (BD Biosciences, State of New
Jersey, U.S.A). To further analyze cell death, Annexin-V
FITC/PI staining was performed on cells treated using
the method just described, according to the manufac-
turer’s instructions.
DAPI staining
Cells were plated in 6-well plates (1.2 × 105cells/well).
Following treatment with DHQ3 or 17-DR for 24 h, the
cells were fixed with paraformaldehyde for 10 min at 4 °
C, washed twice with ice-cold PBS and incubated with
100 μL of DAPI solution (2 μg/mL) for 5 min in the
dark. After washing three times with PBS, the cells were
observed using an IX71 fluorescence microscope (Olym-
pus, Tokyo, Japan). Cells death was characterized by
chromatin condensation and nuclear fragmentation.
Measurement of intracellular ATP
Cells (1.2 × 105 cells/well) were seeded in a 6-well plate for
24 h prior to incubation with diverse concentrations of
analogs for 5 h. To measure intracellular ATP levels, we
used a luminometric-based ATP Assay kit according to
the manufacturer’s protocol. The signal was measured by
a Luminoskan luminometer (Thermo Scientific, Atlanta,
GA, USA). The ATP concentration with each treatment
was calculated as a percentage of that of the control.
Evaluation of cell death form by electron microscopy
Cultured cells were washed and fixed with 2 % parafor-
maldehyde and 3 % glutaraldehyde in 0.1 M PBS
(pH 7.4) at 4 °C. Then, the cells were post-fixed with
1 % osmium tetroxide for 1.5 h, washed once and treated
with 3 % aqueous uranyl acetone, before being dehy-
drated with a graded series of ethanol and acetone and
embedded in Araldite. Thin sections were cut using a
Reichert ultramicrotome (Leica, Wetzlar, Germany),
post-stained with 0.3 % lead citrate, and examined by
TEM (Olympus JEOL, Peabody, MA, USA).
Western blot analysis
Cells were harvested and homogenized in RIPA lysis buffer
for 30 min on ice, the lysates were centrifuged at 12,000 × g
for 30 min at 4 °C. A bicinchoninic acid (BCA) assay was
used to detected protein concentrations. Equal amounts of
total protein were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to polyvinylidene fluoride (PVDF) membranes. After
the membranes were blocked with 5 % skim milk in PBS
with 0.1 % Tween20 for 4 h, they were incubated overnight
at 4 °C with primary antibodies, followed by incubation
with the corresponding secondary antibodies. The mem-
branes were imaged with gel imaging equipment (Bio-Rad,
USA). β-actin was used as a loading control.
Immunofluorescence
Cells in 12-well plates (1.2 × 105 cells/well) were cultured
to reach exponential growth prior to being treated with
varying concentrations of analogs for 24 h. After treat-
ment, cells were fixed with paraformaldehyde for
15 min, permeabilized for 10 min in 0.2 % Triton X-100,
and incubated for 2 h in blocking buffer (5 % BSA in
PBS). Next, cells were incubated with RIP1 or RIP3 anti-
body overnight at 4 °C, and visualized with FITC-
conjugated Goat Anti-Rabbit IgG. The nuclei were
stained by incubating cells with 2 μg/mL DAPI in PBS
and then washed extensively with PBS. Images were ob-
tained by fluorescence microscopy.
Small interfering RNA transfection
The RIP1 and RIP3 siRNAs were obtained from Gene-
Pharma (China). The siRNA were transiently transfected
into MDA-MB-231 cells in 6-well plates using 10 μL Lipo-
fectamine 2000 reagent (Invitrogen, USA) according to
the manufacturer’s protocol. After 48 h of transfection,
the cells were collected for immunoblot analysis as de-
scribed earlier. The sequences of siRNA used for experi-
ments of human RIP1 siRNA and RIP3 siRNA were as
follows: Negative control sense, 5’-UUC UCC GAA CGU
GUC ACG UTT-3’and antisense, 5’-ACG UGA CAC
GUU CGG AGA ATT-3’; Positive control sense, 5’-UGA
CCU CAA CUA CAU GGU UTT-3’ and antisense, 5’-
CUU GAG GCU GUU GUC AUA CTT-3’; RIP1-homo-
1980 sense, CCUUCUGAGCAGCUUGAUUTT and anti-
sense, AAUCAAGCUGCUCAGAAGGTT; RIP3-homo-
966 sense, CCGGCUUAGAAGGACUGAATT and anti-
sense, UUCAGUCCUUCUAAGCCGGTT.
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Colorimetric determination of ATPase activity
The assay was performed as previously described with
slight modifications [24, 25]. To prepare the malachite
green reagent, and then, either analog or DMSO control
was added. The plate was incubated for 2.5 h at 37 °C.
Next, 80 μL of malachite green reagent was added to each
well, the plate was shaken and 10 μL of 34 % sodium cit-
rate was added. The samples were mixed thoroughly for
10–20 min before measuring OD650 using a microplate
reader (Synergy HT, BioTek, Vermont, U.S.A).
In vivo experiments
To evaluate if antitumor effects delivered by DHQ3 and
17-DR, we used the female nude mice (4- to 6-weeks
old) to perform experiments, they were obtained from
the animal experimental center of Beijing vitalriver.
MDA-MB-231 cells (3×106 cells per animal) were
injected subcutaneously to induce tumor formation.
Next, 20 mice that developed tumors over 100 mm 3
were randomly divided into five groups (5 mice per
group), 0.2 ml of DMSO, 17-DR (25 mg/kg), DHQ3
(50 mg/kg), DDP (3 mg/ kg) were intraperitoneally
injected every 3 days, and body weight was monitored
before each injection. Tumor volume was measured as
length x width2/2. After treatment 21 days with drugs,
the solid tumors were removed and stored in 4 % forma-
lin solution, cut into small pieces that were stained with
hematoxylin and eosin (H&E).
Statistical analysis
Values are expressed as the means ± SEM of three experi-
ments. SPSS v.16.0 software (SPSS Inc., Chicago, IL, USA)
was used for data analysis. Comparisons between two
groups were analyzed using the two-tailed Student’s t-test.
A p-value < 0.05 is considered statistically significant.
Results
Inhibition of MDA-MB-231 cell proliferation with varying
concentrations of DHQ3 and 17-DR
To investigate the effects of DHQ3 and 17-DR on breast
cancer cells, MDA-MB-231 cells were treated with dif-
ferent concentrations of DHQ3 and 17-DR for 24, 48 or
72 h. As determined by MTT assays, DHQ3 and 17-DR
significantly inhibited MDA-MB-231 cell growth (Fig. 1a
and b), the cell viability rates were gradually reduced
with the increase of analogs concentration (p < 0.01).
Furthermore, we observed that DHQ3 and 17-DR could
inhibit MDA-MB-231 cells colony formation by increas-
ing concentrations (Fig. 1c).
DHQ3 and 17-DR induce different forms of cell death in
MDA-MB-231 cells
Similarly, MDA-MB-231 cells were treated with DHQ3 or
17-DR for 24 h and then flow cytometry was used to
detect dead cells. As expected, PI-staining indicated an in-
crease in the ratio of dead cells with increasing analog
concentrations (Fig. 2a), suggesting that both analogs in-
duce cell death in MDA-MB-231 breast cancer cells.
Annexin-V FITC/PI staining gave similar results, with 17-
DR treatment, we could see a large number of early stage
apoptotic cells were in the AV + PI- quadrant (Fig. 2b).
With analog treatment, DAPI-stained cells exhibited con-
densed and fragmented nuclei, which is indicative of cell
death (Fig. 2c). Furthermore, it has been debated whether
the function of Hsp90 is ATP dependent. It was found
that cellular ATP levels were reduced with DHQ3 and 17-
DR treatment (Fig. 2d), suggesting that the analogs in-
duced cell death by decreasing ATP levels. To further de-
fine the types of cell death obtained with analogs
treatment, we observed cells under an electron micro-
scope (Fig. 2e). DHQ3 induced typical nuclear fragmenta-
tion, loss of plasma membrane integrity, and organelle
(especially mitochondrial) swelling. At the same time, cells
treated with 17-DR showed typical characteristics of apop-
tosis: nucleus concentrating, condensation and margin-
ation of nuclear chromatin, and nuclear membrane and
plasma membrane and organelles intact.
17-DR-induced apoptosis is caspase-dependent
To verify whether the 17-DR-induced cell death ob-
served in MDA-MB-231 cells was a result of apoptosis,
western blot analyses were conducted to measure the
levels of apoptosis proteins. Apoptosis was induced in
breast cancer cells by 17-DR as confirmed by the down-
regulation of Mcl-1 and Bcl-2, and up-regulation of Bax
protein levels (Fig. 3a). Further, we performed immuno-
blotting to detect caspase activation. The cleaved prod-
ucts of caspase-3, caspase-8 and PARP were detected
(Fig. 3b), indicating that 17-DR-induced cell death was
apoptotic. Furthermore, we pre-treated cells with the
necroptosis inhibitor, Nec-1 or the caspase inhibitor, z-
VAD-fmk. The effects of 17-DR were decreased by treat-
ment with the apoptosis inhibitor z-VAD-fmk (Fig. 3c),
the cell viability was (51.59 ± 1.27) % when 17-DR used
alone, increased to (66.34 ± 3.25) % in conjunction with
z-VAD-fmk (p < 0.01), but not by Nec-1 (Fig. 3c and d),
indicating a caspase-independent killing mechanism.
Hsp90 inhibitor DHQ3 induces necroptosis in breast
cancer MDA-MB-231 cells
Unlike 17-DR treated cells, cleaved products of caspase-3
and caspase-8 were nearly undetected in DHQ3 treated
cells (Fig. 4a). Next, we found that DHQ3 up-regulated
expression of RIP1, RIP3 and MLKL (Fig. 4b). In addition,
DHQ3 significantly promoted the nuclear translocation of
RIP1 and RIP3 (Fig. 4c), they showed DHQ3 increased the
expression of RIP1 and RIP3 on the cytoplasm. The viabil-
ity of DHQ3-treated cells was rescued with Nec-1 pre-
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treatment (Fig. 4d), there was an increase [(87.39 ± 0.75) %]
in conjunction with Nec-1 (p < 0.01) compared to DHQ3-
treated alone [(66.32 ± 0.39) %]. As proven by Annexin-V
FITC/PI staining (Fig. 4e), DHQ3/Nec-1 induced less cell
death than did DHQ3 alone. Nec-1 significantly protected
the cells from DHQ3-induced, reducing right quadrant
populations from 31.1 to 18.7 %. On the other hand, z-
VAD-fmk did not protect against DHQ3-induced cell death
(Fig. 4d). These results demonstrated that DHQ3 induced
necroptosis in breast cancer MDA-MB-231 cells.
Knockdown of RIP with siRNA protected MDA-MB-231
cells against DHQ3-induced necroptosis
To characterize the mechanisms underlying sensitization to
the analogs, we investigated the effect of RIP1 and RIP3
knockdowns on the signaling pathway in MDA-MB-231
cells. Results shown in Fig. 5 demonstrated that silencing
RIP1 and RIP3 expression prevented DHQ3 from activating
cell death, and caused the loss of Nec-1’s protective effect.
However, silencing RIP1 expression (Fig. 5a) did not
affect 17-DR-induced cell death, as shown in the
MTT and Annexin-V FITC/PI results (Fig. 5b and c).
In the normal, the viability was (87.39 ± 0.70) % when
combined with Nec-1, compared (65.75 ± 0.60) % that
treated DHQ3 alone; after the silence of RIP1, the
viability was (74.67 ± 5.61) % in conjunction with
Nec-1, compared (78.42 ± 3.22) % that treated DHQ3
alone. The same results occurred when RIP3 was si-
lencing (Fig. 5d). The cell viability were (63.53 ± 1.44)
% and (72.95 ± 2.91) % in the before and after pro-
cessing RIP3 silence when treated DHQ3 alone, and
changed to (85.84 ± 2.33) % and (73.94 ± 4.76) % when
combined with Nec-1 (Fig. 5e). Consistent with MTT
results, the Annexin-V FITC/PI results approved
again, Nec-1 lost its protection for DHQ3 (Fig. 5f ).
Altogether, these data demonstrated that in MDA-MB-
231 cells DHQ3 induced necroptosis, which can be mim-
icked by down-regulation of RIP1 and RIP3.
Fig. 1 Inhibitory effects of DHQ3 and 17-DR on MDA-MB-231 cells. a MDA-MB-231 cells were treated with various concentrations of analogs for 24, 48
or 72 h. Cell viability was measured by MTT assay. *p < 0.01, **p < 0.001. b Cells were treated with analogs for 24 h and the morphology was examined
by light microscopy with differential interference contrast optics. c The colony-forming capability of MDA-MB-231 cells was measured using a colony
formation assay after treatment with various concentrations of analogs for 5 days
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DHQ3 and 17-DR down-regulate Hsp90 client proteins in
breast cancer MDA-MB-231 cells
Hsp90 inhibitors have been established as a method of
targeting Hsp90 client onco-proteins [26–28] and pro-
moting apoptosis of tumor cells [29]. The isolated ana-
logs were tested for their ability to inhibit yeast Hsp90
activity using the malachite green ATPase assay. Using
the optimized reaction conditions, DHQ3 and 17-DR
presented stronger ATPase inhibition activity compared
to the original Hsp90 inhibitor, GA (Fig. 6a). To confirm
the regulation of Hsp90 by DHQ3 and 17-DR, the ex-
pression levels of its client proteins were examined,
Fig. 2 DHQ3 and 17-DR induced various forms of death in MDA-MB-231 breast cancer cells. a Flow cytometric analysis of cell death after treatment with
DHQ3 or 17-DR for 24 h using PI staining. b Cells treated with analogs for 24 h were analyzed using an Annexin V-FITC/PI assay. c Cells were treated with
the indicated concentrations of analogs for 24 h, subjected to DAPI staining (showing nucleus) and visualized by fluorescence microscopy. White
arrowheads indicate dead cells. d Reduction in ATP production after analogs treatment. Cellular levels of ATP were measured after 5 h. e DHQ3 induced
necroptosis, while 17-DR induced apoptosis in MDA-MB-231 cells. Electron microscopy of cells treated for 24 h with DMSO, 200 μM DHQ3 or 200 μM
17-DR. White arrowheads denote chromatin pyknosis in cells treated with 17-DR
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including Akt, Her2, CDK4, C-Raf, HIF1α and EGFR
[3, 30]. Western blot analysis demonstrated that these
classical client proteins were significantly down-
regulated in the presence of DHQ3 and 17-DR
(Fig. 6b). Several reports have suggested that the de-
crease in expression levels of Hsp90 client proteins is
due to their degradation by the proteasome. Indeed, a
1 h pre-treatment with the proteasome inhibitor
MG132 was sufficient to partly restore the expression
level of client proteins in cells incubated with DHQ3
or 17-DR (Fig. 6c).
In vivo antitumor efficacy of 17-DR or DHQ3
To test whether 17-DR or DHQ3 show any antitumor
effects in vivo, MDA-MB-231 cells were xenografted
into nude mice, and then the tumor-bearing animals
were treated with 17-DR (25 mg/kg/3days) or DHQ3
(50 mg/kg/3days) for 21 days by intraperitoneal injec-
tion. We observed that 17-DR or DHQ3 prevented
tumor growth (Fig. 7a) compared with the control.
Obvious body weight loss was observed after treat-
ment with DHQ3 and 17-DR (Fig. 7b). When each
animal was considered individually, the incidence of
Fig. 3 17-DR induced apoptosis in MDA-MB-231 cells that is dependent of caspase activity. a Whole-cell lysates from the MDA-MB-231 cells treated
with different concentrations of 17-DR, or treated with 200 μM 17-DR for different lengths of time, were subjected to western blot analysis. b The
expression of caspase-3, −8 and PARP. 17-DR increased their activation at 24 h. c Analysis of cell viability by MTT assay, following treatment with 17-DR
with or without 1 h pre-treatment with Nec-1 or z-VAD-fmk. *P < 0.05. d Annexin V-FITC/PI analysis following treatment with 17-DR alone or with
Nec-1 pre-treatment
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mice progressing with a tumor volume of 500 mm3
was significantly diminished by day 15 in DHQ3/17-
DR-treated animals compared with controls (Fig. 7c).
Consistent with body weight data, 17-DR- or DHQ3-
treated groups exhibited obvious decrease in tumor
weight (Fig. 7d). Aspartate aminotransferase (AST)
and alanine-aminotransferase (ALT) are commonly
used as biomarkers for the evaluation of hepatotox-
icity [31], after the treatment of 17-DR or DHQ3, the
levels of AST and ALT were analyzed using an activ-
ity assays, showing that 17-DR and DHQ3 had nearly
no effect on the AST and ALT compared with those
of the control group, but obviously lower than those
of the DDP-treated group (Fig. 7e). H&E staining of
the organs such as the liver, lung and kidney demon-
strate that there was no serious damage (Fig. 7f ). All
of the results provided evidence for its anti-
tumorigenic action with low hepatotoxicity in vivo.
DHQ3 and 17-DR do not induce different forms of death
in other cancer cell lines
Based on these interesting data, a series of cancer cell
lines were treated with the same concentrations of
DHQ3 or 17-DR, as well as pre-treated with Nec-1, as in
Fig. 4 DHQ3 induced necroptosis in MDA-MB-231 cells. a Cells were treated with DHQ3 for 24 h. Cell lysates were prepared and examined using
western blot analysis. b The expression of necroptosis-related proteins was analyzed by western blot. c MDA-MB-231 cells were incubated with
DHQ3 for 24 h and treated with primary antibodies overnight at 4 °C. The localization of the target proteins was assessed by immunofluorescence
staining. Nuclei were stained with DAPI. Scale bar is 50 μm. d Cells incubated with DHQ3 (200 μM) for 24 h, with or without 1 h pre-treatment
with Nec-1 or z-VAD-fmk, were analyzed by the MTT assay. *P < 0.05. e MDA-MB-231 cells treated with DMSO, Nec-1 (20 μM), DHQ3 (200 μM)
alone or with Nec-1 pre-treatment, were analyzed by Annexin V-FITC/PI assay
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the experiments with MDA-MB-231 cells (Fig. 8). Under
the conditions used, the same phenomenon of different
forms of cell death with different analogs was not ob-
served in these other cancer cell lines. Remarkably, com-
bined with Nec-1 rescued MCF-7, MDA-MB-231, T-47D
cells to DHQ3. However, Nec-1 did not rescue HepG2,
SMMC7721, CNE-2Z, HNE1, A549, SGC7901, ISK and
SW480 cells from DHQ3-induced cell death at all.
Discussion
The MDA-MB-231 cell line is a type of triple-negative
breast cancers (TNBC), which has been tested negative
for estrogen receptors, progesterone receptors and
HER2 [32]. Relatively few drugs work against TNBC,
and there is a lack of standardized medication guidelines
for TNBC. The expression of Hsp90 in tumor cells is 2–
10 times higher than in normal cells, therefore, Hsp90
inhibitors could show selectivity towards tumor cells,
yielding specific antitumor effects [7, 33]. In study,
DHQ3 and 17-DR presented potent antitumor activity
for TNBC in vitro and in vivo.
On the basis of the strong ties between Hsp90 and
carcinogenesis, a significant proportion of the work
on Hsp90 inhibitors have been committed to develop-
ing derivatives of GA, including 17-AAG and 17-
ABAG [34–37]. However, there seems to be a limit to
Fig. 5 Knockdown of RIPs with siRNA protected against DHQ3-induced necroptosis in MDA-MB-231 cells. a, d MDA-MB-231 cells were transfected
with control, or RIP1 or RIP3 siRNA, and after 48 h, whole-cell lysates were subjected to western blot analysis. b, e After 24 h transfection with
RIP1/RIP3 siRNA, cells were treated with 200 μM of analogs for another 24 h, with or without 1 h pre-treatment with Nec-1 and z-VAD-fmk. Cell
viability was measured by MTT assay. *P < 0.05. c, f Similarly to b, MDA-MB-231 cells were analyzed by Annexin V-FITC/PI assay
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further development of most of these inhibitors.
Therefore, there is a need for further analysis of ana-
logs. Our findings indicated that the new non-
quinone GA analogs DHQ3 and 17-DR have high ac-
tivity against a series of cancer cells, especially MDA-
MB-231 cells. As Hsp90 inhibitors, they were tested
for the ability to inhibit yeast Hsp90 activity using a
malachite green ATPase assay, and displayed stronger
inhibition of ATPase activity than GA. Furthermore,
down-regulated the levels of Hsp90 client proteins,
and the degradations of these client proteins were
blocked by treatment with the proteasome inhibitor
MG132. More importantly, the result of this study
showed that DHQ3 and 17-DR have potent inhibitory
effects on MDA-MB-231 breast cancer cell tumor
growth, and showed low hepatotoxicity in vivo and
no serious side effects.
Interestingly, DHQ3-induced necroptosis is dependent
on RIP1 and RIP3, a classical mode of necroptosis, while
17-DR-treated cells display the characteristic changes of
apoptosis. We found that 17-DR regulates apoptosis-
related proteins, and that it induces apoptosis of MDA-
MB-231 cells in a caspase-3, −8 dependent manner. Our
data also demonstrated that treatment with DHQ3
resulted in significant induction of necroptosis associ-
ated with expression of RIP. Recent research has under-
lined RIP3 as a key protein regulating the switch
between TNF-induced necroptosis and survival, and in-
dicated that the complex containing RIP3 could function
as a “necrosome” which differ from other complexes that
induce apoptosis or NF-kB activation [17, 18, 38]. The
state of RIP determines whether it functions as a mol-
ecule that promotes or inhibits cell death [39]. Our work
showed that DHQ3 treatment markedly increased the
level of RIP1 and RIP3 in MDA-MB-231.
It is puzzling that the two analogs with similar struc-
ture would guide MDA-MB-231 cells towards two differ-
ent cell death programs. In our siRNA studies, we
clearly demonstrated the importance of RIP1 and RIP3
in the death process. The data indicate that knockdown
of RIP1 and RIP3 expression inhibit DHQ3-induced
necroptosis, and cause the loss of protective effect of
Nec-1, but has no effect on 17-DR-induced apoptosis.
Furthermore, it has been revealed that GA accelerates
the molecular switch from necroptosis to apoptosis via
RIP1 down-regulation in TNF-stimulated L929 cells
[40]. As described above, RIP is one of the client protein
of Hsp90, therefore we hypothesize that the two Hsp90
Fig. 6 DHQ3 and 17-DR induced the degradation of Hsp90 client proteins. a Hsp90 ATPase activity at different concentrations of GA, DHQ3 and
17-DR were tested by the malachite green-phosphate and ammonium molybdate method. At the given times, the reaction was stopped and the
OD650 value measured. b Cells were treated with analogs at different concentrations or different lengths of time, the Hsp90 client proteins were
assessed by western blot. c MDA-MB-231 cells were pretreated with 10 μM MG132 for 4 h, with or without a subsequent 24 h incubation with
200 μM DHQ3 or 200 μM 17-DR. Whole-cell lysates were subjected to western blot analysis
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Fig. 7 DHQ3 and 17-DR significantly delays MDA-MB-231 tumor growth. a Representative tumors from each treatment group. b Body weight of
the mice. c Tumor volume of the mice. d Tumor weights after DHQ3, 17-DR and DDP treatment. e In vivo hepatotoxicity evaluation of DHQ3 and
17-DR in nude mice. The AST and ALT were determined by Assay Kit. The blood serum samples were treated according to the manufacturer’s
instruction. And the AST and ALT activities are expressed as U/L. f H&E-stained sections of the tumor, liver, lung and kidney from the mice
after treatment
Fig. 8 MTT results of DHQ3 and 17-DR on ten human cancer cell lines. HepG2, SMMC7721, MCF-7, MDA-MB-231, T-47D,CNE-2Z, HNE1, A549, SGC7901,
ISK, SW480 were exposed to 200 μM analogs as in previous experiments with MDA-MB-231 cells for 24 h, with or without pre-treatment with Nec-1.
The cell survival rates were assessed using MTT assays. *P < 0.05
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inhibitors induce different forms of death by having
slightly different effects on RIP. This is of importance
and merits further investigation. Further, in-depth test-
ing is required to determine the efficacy.
Conclusions
In summary, the two new non-benzoquinone GA ana-
logs, DHQ3 and 17-DR, inhibited the proliferation of
MDA-MB-231 cells by decreasing the expression of
Hsp90 client proteins. They have potent inhibitory ef-
fects on MDA-MB-231 breast cancer cell tumor growth
with low hepatotoxicity. Importantly, our observations
revealed that they triggered different forms of death in
MDA-MB-231 cells. DHQ3 functions as an Hsp90 in-
hibitor and a necroptosis inducer, while 17-DR induces
caspase-dependent apoptosis.
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